14 January 2011
Smiths Group confirms that it has received an approach for Smiths Medical which it has rejected.
The value offered was £2.45 billion in cash, as a best and final offer, subject inter alia, to extensive due diligence and completion of financing.
The Board has carefully considered this approach with its advisers and has concluded that it would not be in the interests of shareholders to pursue discussions on the basis of an indication at this price level.
In reaching this conclusion, the Board has taken into account the quality and highly cash generative nature of Smiths Medical, both standalone and in the context of the Group as a whole.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
![Davinci Gen V Gen Front View[36]](/media/wlocq5n4/davinci-gen-v-gen-front-view-36.jpg?width=431&height=214&format=webp&quality=100&v=1dbb81c2473de50)
Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket
Read our latest company news as Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket
Find out more
Smiths Detection secures deal to supply systems to major cruise lines
Find out more
Smiths Interconnect expands EMEA cable harness production capacity
Smiths Interconnect, announces the expansion of its cable harness production capacity at its facility in Tunisia, an investment for growth in support of all its EMEA production sites.
Find out more
